The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Gold and silver prices are at record highs, and many are saying we’re at the start of a commodity supercycle. The ASX stands well poised to benefit, given our high concentration of mining companies listed on the bourse, and YTD, we’re seeing evidence of that as we climb back towards 8,900pts on the XJO.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

And it’s not only local investors who are paying attention, but those offshore, too. One such investor and entrepreneur is Monaco-based marketeer Markus Meister.

In this Expert Exchange video, Meister speaks to HotCopper‘s senior markets reporter Jonathon Davidson about why he sees upside yet to come for Vertex Minerals (ASX:VTX), and other players in the gold space on the ASX.

Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

More From The Market Online
China birthrate concept

Why are A2 Milk shares falling on Monday? Look no further than… Chinese birth data

A2 Milk has fallen so steeply that its issued a halt, clearly after deciding a -10.5%…
The Market Online Video

Australia economic outlook CY26: What the year will mean for your money

This week on Money and Investing, Mitch Olarenshaw and I take a hard look at Australia’s economic outlook for CY26 and what it
The Market Online Video

The ASX Today: Tariffs, trade war, and economic threats back to kick off 2026; metal bats out of hell

Greetings and welcome to HotCopper’s market update for Monday, Week 4, I’m Jon Davidson.
FDA cpmce[t

Mesoblast dips on confusion around FDA advice on stem cells for back pain

Mesoblast (ASX:MSB) has seen its shares dip on Monday morning out the gate as some investors struggle to digest